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ABSTRACT 
Background:   Precision medicine is heralded as offering more effective treatments to smaller 
targeted patient populations. In breast cancer, adjuvant chemotherapy is standard for 
patients considered high risk after surgery. Molecular tests may identify patients that can 
safely avoid chemotherapy. We used economic analysis prior to a large scale clinicl trial of 
molecular testing to confirm the value of the trial and help prioritise between candidate tests 
as randomised comparators. 
Methods: Women with surgically treated breast cancer (ER positive and lymph node positive 
or tumour size >=30mm) were randomised to standard care (chemotherapy for all) or test-
directed care using Oncotype DX. Additional testing was undertaken using alternative tests: 
MammaPrintTM, PAM-50 (ProsignaTM), MammaTyperTM, IHC4 and IHC4-AQUA™ (NexCourse 
Breast™). A probabilistic decision model assessed cost-effectiveness of all tests from a UK 
perspective.  Value of information analysis (VoI) determined the most efficient publically 
funded ongoing trial design in the UK.  
Results:   There was an 86% probability of molecular testing being cost-effective, with most 
tests producing cost savings (range -£1,892 to +£195) and QALY gains (range 0.17 to 0.20). 
There were only small differences in costs and QALYs between tests. Uncertainty was driven 
by long-term outcomes. VoI demonstrated value of further research into all tests, with 
ProSigna currently highest priority for further research. 
Conclusion:    Molecular tests are likely to be cost-effective, but an optimal test is yet to be 
identified. Health economic modelling to inform the design of an RCT looking at diagnostic 
technology has been demonstrated feasible as a method for improving research efficiency. 
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HIGHLIGHTS 
Multi-parameter and genomic tests in breast cancer are undergoing rapid development and 
implementation in lymph node negative breast cancer. There remains substantial uncertainty 
about the efficacy and cost-effectiveness of such tests when used in higher risk patients. 
There are major challenges in undertaking meaningful research to inform reimbursement and 
adoption decisions for these diagnostic tests and for personalised medicine technologies in 
general.  
In this context, we describe how the use of value of information analysis as the primary 
outcome of a randomised controlled feasibility trial, in the presence of multiple competing 
technologies, has led to the setup of a major national study which is directly designed to 
inform an estimate of the cost-effectiveness of a personalised treatment strategy in clinically 
high risk early breast cancer.   
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BACKGROUND 
There is increasing concern in developed nations that health care costs are increasing at an 
unsustainable rate. Precision medicine has been heralded as a solution by providing more 
effective treatments to smaller targeted patient populations. In the context of breast cancer, 
adjuvant chemotherapy is offered to most women with invasive breast cancer involving the 
axillary lymph nodes or with otherwise clinically high risk disease.1–4 As a universal 
recommendation chemotherapy is, however, not strongly supported by randomised clinical 
evidence in women who are post-menopausal, of older age and who have oestrogen receptor 
(ER) positive HER2 negative cancer.5 It is therefore likely that many women with ER positive 
breast cancer are being offered chemotherapy with only limited benefit and substantial risk 
of harm.6–8 Diagnostic tests that help identify which women can safely avoid chemotherapy 
could improve health outcomes as well as ease the pressure on strained health system 
budgets. 
Molecular tests may select patients who can safely be spared chemotherapy under the 
rationale that the sensitivity of tumours to chemotherapy is dependent on underlying cancer 
biology, not just clinical and pathological factors. Such new technologies are evolving rapidly 
with an increasing number of commercial and academic institutions offering solutions. 
Different tests contain different combinations of molecular markers and identify different 
patients as at high or low risk of recurrence, but their comparative diagnostic properties 
remains largely unknown.[Ref – not all tests are equal] The maturity of evidence for these 
tests is very variable and traditional methods for generating level one evidence may lack 
efficiency. There is a risk that  technologies entering the market first will be adopted, thereby 
stifling the development of evidence for alternative tests that are currently less well 
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developed but which may emerge as better tests for widespread implementation in the 
future. 
A prospective randomised controlled trial is necessary to measure the clinical utility and cost-
effectiveness of molecular testing in this patient population. Such a trial requires large 
numbers of patients with at least 5 years of follow-up to capture relevant outcomes. The 
randomised comparison of multiple tests in this context is likely to be prohibitive in terms of 
scale and cost. Realistically there are only enough resources available to study one test in an 
adequately powered trial. It is essential that a test chosen to be to focus of such a trial is that 
which has the highest likely long term societal return on that research investment. 
OPTIMA prelim (ISRCTN42400492)9 was established as a feasibility trial prior to an adequately 
powered phase three randomised controlled trial of molecular testing in early breast cancer 
in the UK (Figure Supplementary 1). The objectives were: (i) to evaluate the performance and 
health-economics of alternative molecular tests to determine which technology(s) are to be 
evaluated in a subsequent main trial; (ii) to establish the acceptability to patients and 
clinicians of randomisation to test-directed treatment assignment; and (iii) to establish 
efficient and timely sample collection and analysis essential to the delivery of molecular tests 
driven treatment.  We report here the results of the health-economic analysis and value of 
information analysis designed to inform the selection of a test for study in the subsequent 
OPTIMA trial. 
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METHODS 
The OPTIMAprelim trial 
The design of OPTIMA prelim is described in the protocol available to download on the 
funder’s website (http://www.nets.nihr.ac.uk/projects/hta/103401).  Eligible patients were 
women aged ≥40 with ER positive, HER2 negative clinically high risk (1-9 axillary lymph nodes 
involved, or node negative with a tumour ≥30mm) surgically treated early invasive breast 
cancer.  Women were randomised (1:1) to standard treatment (chemotherapy followed by 
endocrine therapy) or to test guided therapy (endocrine therapy alone if low risk, standard 
treatment if high risk). Oncotype DX was used to direct therapy with a cut-point of >25. 
Chemotherapy was selected from regimens commonly used in the NHS.  
Molecular tests 
Additional molecular tests were conducted on all patients with available samples to enable a 
comparison of the allocation of participants into high or low-risk groups by each test. Several 
alternative tests were considered: Oncotype DX™ (Genomic Health), 
MammaPrintTM/BluePrintTM/TargetPrintTM (Agendia, Irvine, California), ProsignaTM Subtype 
and ProsignaTM ROR_PT, MammaTyperTM (Stratifyer/BioNTech Diagnostics, Mainz, Germany), 
NexCourseTM Breast by Aqua (Genoptix Medical Laboratories, Carlsbad, California – hereafter 
referred to as IHC4 AQUA) and IHC4 performed by conventional pathology techniques (HER2 
testing by ISH and ER, PgR and Ki67 by quantitative image analysis (Ariol) using standard 
immunohistochemistry).  Tests were performed by the vendor (Oncotype DX, MammaPrint/ 
BluePrint, MammaTyper, NexCourse Breast by Aqua or in the Ontario Institute of Cancer 
Research (IHC4, Prosigna using equipment and reagents supplied by the vendor).  Tumours 
were categorised according to the tests pre-defined cut-points into low/intermediate risk 
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(termed low risk) or mid/high risk (termed high risk); for the purpose of this study, the 
Oncotype DX RS cut-point of 25 was used to define a high versus low risk test result.  
Economic modelling method 
The methods for the economic analysis followed the guidelines and reference case of the UK 
National Institute of Health and Care Excellence (NICE).10 A simulation model representing 
the clinical pathway estimated expected costs and quality-adjusted life-years (QALYs) for a 
cohort of women with high risk ER positive HER2 negative early breast cancer. The analysis 
was conducted from a UK NHS perspective, uses a lifetime horizon truncated at age 100 and 
1 year cycle lengths. Costs are reported in 2012/13 GBP (£) and future costs and benefits are 
discounted at an annual rate of 3.5%. The model was analysed using the statistical package 
R.11  
The model structure was based on a previously published model,12 and consists of an initial 
decision-tree (Figure 1a) followed by a seven health-state time-dependent discrete-state 
transition (modified Markov) cohort model (Figure 1b). The model structure was validated 
through consultation with clinical experts within the trial management group. 
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Model Parameters 
Full details of how the model parameters were defined are provided in the supplementary 
material (Table S3). Briefly, the allocation of patients into high- and low-risk groups was based 
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on the OPTIMA prelim study. Cancer recurrence rates for the OPTIMA-prelim patients were 
estimated using 10 year forecasts from Adjuvant! Online.13 The effect of chemotherapy on 
recurrence free survival dependent on test score was taken from the SWOG 8814 trial by 
modelling the log hazard ratio for 10 year recurrence free survival as a linear function of the 
Oncotype DX Recurrence Score (RS).14 For other tests, representative uncertainty was 
introduced into the model using an uncertain prior distribution for the predictive effect from 
which weighted sampling depended on the degree of discordance between the test and 
Oncotype DX seen in OPTIMA prelim.  
Healthcare costs and quality of life 
The cost of tests was determined by using the current public list price (Oncotype DX, 
MammaPrint, IHC4 AQUA) or, in the absence of a public list price, by communication with the 
manufacturer (Prosigna) or by best estimate by the analyst following discussion with the 
manufacturer (MammaTyper). For locally performed tests (MammaTyper, Prosigna and IHC4) 
the capital costs and per-patient costs to the NHS were estimated by consultation with NHS 
service managers, pathologists and manufacturers. Where uncertainty existed about the 
costs, this was represented by a distribution in the probabilistic analysis.  
Chemotherapy procurement, delivery and toxicity costs were taken from the British National 
Formulary, the NHS Commercial Medicines Unit and NHS Reference costs.15–17 The 
proportions, case-mix and test selection of patients treated with anthracycline plus taxane, 
anthracycline alone, or taxane alone were modelled directly from the OPTIMA prelim data. 
Costs of cancer recurrence and long term toxicities were taken from a bespoke costing study 
of NHS patients and the published literature.18 Quality of life (utility) values were extracted 
from a previously published study and assigned to each model health state, including a 
decrement for chemotherapy toxicity.19 
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Sensitivity analyses 
Probabilistic sensitivity analysis was conducted using Monte Carlo simulation to sample from 
distributions assigned to model input parameters. In addition, two alternative model 
specifications were analysed to explore key structural uncertainties: 
1. Sensitivity analysis on the chemotherapy effect. The assumption of a predictive 
treatment effect was challenged in a sensitivity analysis that assumed constant 
relative benefit from chemotherapy across all risk groups based on the Oxford 
Overview meta-analysis applied over a 5-year period.20 
2. Sensitivity analysis on survival after recurrence - in the base-case analysis the survival 
after distant recurrence was assumed to be constant across groups. In a sensitivity 
analysis, survival after recurrence was assumed to depend on whether patients had 
previously received adjuvant chemotherapy.  
Value of Information analysis 
Value of information analysis is a powerful method for assigning a value to future planned 
research.21–23  It relies on the theory that if the evidence for the effectiveness or cost-
effectiveness of a new technology is uncertain then we risk making a sub-optimal decision 
about which to adopt for use in a population of patients. Making a suboptimal adoption 
decision has the consequence of lost health or lost resources compared to an optimal 
decision. The reduction in decision uncertainty therefore has quantifiable value. The results 
of the value of information analysis were presented using the following statistics:  
 Expected Net Health Benefit is the central measure of cost-effectiveness expressed in 
terms of QALYs, assuming a societal willingness to pay threshold value of £20,000 per 
QALY.  
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 Expected value of perfect information (EVPI) represents the ceiling value of future 
research. It represents the maximum cost the healthcare funder should be willing to 
spend on future research.  
 Expected value of perfect parameter information (EVPPI) measures the ceiling value of 
future research for a particular model parameter. It represents the maximum cost the 
healthcare funder should be willing to spend on future research for that particular 
parameter.  
 Expected value of sample information (EVSI) measures the actual value of future 
research of a specified design.  
For further information on value of information analysis and its application in health 
technology appraisal please refer to the published literature. EVPPI was calculated using a 
non-parametric regression-based approach.24 EVSI was calculated using nested Monte-Carlo 
simulation.25 
The EVPPI was calculated for the five-year recurrence free survival parameters and other 
parameters that would be informed by the proposed OPTIMA trial (choice of chemotherapy 
regimen, benefit from chemotherapy, the proportion allocated to high risk by each test, short 
term chemotherapy toxicity and costs). This represents a ceiling on the value of research in 
the context of a randomised controlled trial with 5 years of follow up. Each EVPPI calculation 
is the EVPPI for a comparison between chemotherapy for all and chemotherapy directed by 
a single alternative test. Tests with higher EVPPI therefore have a higher societal priority for 
inclusion in further randomised research which has five-year recurrence free survival as an 
outcome. 
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RESULTS 
The OPTIMA prelim trial recruited 313 patients between October 2012 and June 2014 in 31 
UK centres of whom 302 had samples available for molecular testing.  The mean age was 58, 
68% of patients were post-menopausal and 64% had 1-3 nodes involved (Table 1). The 
proportion of patients considered as low-risk by each test and therefore potentially spared 
chemotherapy ranged from 0.82 (Oncotype DX) to 0.55 (IHC4-AQUA) (Table 2).  Based on the 
intended chemotherapy regimen for each patient and the proportion allocated to high or low 
risk by each test, the expected mean costs of chemotherapy ranged from £3,611 per patient 
(all patients treated with chemotherapy) to £2,102 per patient (Prosigna-ROR). The 
correlation coefficients between 10 year predicted recurrence free survival and test scores 
(where continuous readout available) were 0.24, 0.36, 0.17 and 0.14 for Oncotype DX, 
Prosigna ROR, IHC4 and IHC4-AQUA respectively.  
Table 1. Patient characteristics 
CHARACTERISTIC TOTAL 
n % 
No. of patients 302  
Age years (Median(Range))  58 (40-78) 
Menopausal status of participant   
 Pre/peri-menopausal 97 32 
 Post-menopausal 205 68 
Number of involved nodes   
 None 57 19 
 1-3 192 64 
 4-9 42 13 
 +ve sentinel node biopsy without clearance surgery 11 4 
Intended chemotherapy regimen   
 Anthracycline – non-taxane 116 39 
 FEC75-80 86 29 
 FEC90-100 15 5 
 E-CMF 15 5 
 Taxane – non-anthracycline (TC) 34 11 
 Anthracycline – taxane 152 50 
 FEC-T 149 49 
 FEC-Pw 3 1 
Histological grade   
 1 19 6 
 2 201 67 
 3 82 27 
Largest tumour size in mm (Median(Range))  28 (2-170) 
 <=30mm 172 57 
 >30mm 130 43 
Adjuvant! Online 10 year RFS (hormone therapy only)   
  60.5 (22.0-82.1) 
 
14 
 
 
Table 2. Costs of each testing strategy, proportion allocation to high risk group and expected 
chemotherapy costs in OPTIMA prelim. 
TESTING 
STRATEGY 
PROPORTION LOW 
RISK (SPARED 
CHEMOTHERAPY)* 
TESTING COST PER-PATIENT 
(95% CIS) 
MEAN CHEMOTHERAPY 
COST PER-PATIENT** 
FORECAST MEAN 10 YEAR 
RECURRENCE-FREE 
SURVIVAL(%)†† 
Low risk High risk 
CHEMOTHERAPY 
FOR ALL  
0  £3,611                  59.8 
ONCOTYPE DX 0.82 £2,580 (fixed) £678 60.9 54.6 
MAMMAPRINT 0.61 £2,207 (fixed) £1,409 61.6 57.0 
PROSIGNA  
   SUBTYPE  
   ROR 
 
0.59 
0.65 
£1,672.50 (1,576 - 1,773)  
£1,509 
£1,291 
 
62.4 
61.8 
 
55.9 
55.9 
MAMMATYPER 0.62 £1,277† (186 - 6,415) £1,422 61.1 57.5 
IHC4-AQUA 0.55 £720 (fixed) £1,610 60.6 58.7 
IHC4 0.61 £152 (61 - 322) £1,370 60.5 58.5 
*Patients with unavailable test results are assumed to be high risk and are treated with chemotherapy. 
**Average per-patient procurement and delivery costs, based on prescribing intent and test assignment and not including 
costs of toxicity. 
† Unavailable from manufacturer therefore estimated by analyst 
†† Forecast using Adjuvant! Online (treated with hormone therapy but no chemotherapy) 
 
Cost-effectiveness results 
In the base case analysis the expected lifetime per-patient cost if all patients receive 
chemotherapy was £13,961 (95% CI £10,535 - £21,203) and the expected lifetime QALYs was 
7.69 (95% CI 5.06 – 9.58). The mean incremental QALYs with each testing strategy were very 
similar at between 0.17 and 0.20 more than chemotherapy for all, although credible intervals 
were generally around plus or minus 1 QALY (Table 3). The mean incremental cost per patient 
was more variable, between an additional cost of £195 (95% CI £-3,206 - £3,430) with 
MammaPrint to a saving of £1,892 (95% CI -£5,415 - £1,488) with IHC4 in comparison with all 
patients receiving chemotherapy. The Net Health Benefit from all testing strategies was 
higher than for standard care, although was of a very similar magnitude between tests. 
Uncertainty in the cost-effectiveness of all tests was large (Figure 2a and Figure 2b). The 
probability that individual tests are more cost-effective than standard care ranged from 75% 
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(MammaPrint) to 81% (IHC4) in separate two-way comparisons. The incremental analysis, in 
which all tests compete with each other in a multi-way comparison, demonstrated that the 
probability that test-directed chemotherapy using any test is more cost-effective than 
standard care was 86% (Figure 2c).  
Table 3. Cost-effectiveness results – incremental analysis in comparison with all patients 
receiving chemotherapy. 
 Oncotype DX MammaPrint Prosigna Subtype Prosigna ROR MammaTyper IHC4-AQUA IHC4 
Base case analysis 
Mean incremental QALYs 
per Person (95% CI) 
0.2 
(-1.07 – 1.4) 
0.18  
(-0.87 – 1.1) 
0.18  
(-0.85 – 1.05) 
0.18  
(-0.91 – 1.15) 
0.18  
(-0.95 – 1.15) 
0.17  
(-0.87 – 1.05) 
0.18  
(-0.93 – 1.14) 
Mean incremental Cost 
per Person (£) (95% CI) 
-108  
(-4,610 – 4,292) 
195  
(-3,206 – 3,430) 
-281  
(-3,553 – 2,774) 
-474  
(-4,078 – 2,955) 
-944  
(-4,481 – 2,380) 
-1,115  
(-4,373 – 1,943) 
-1,892  
(-5,415 – 1,488) 
ICER (£ per QALY) DOMINATES* 1,097 DOMINATES* DOMINATES* DOMINATES* DOMINATES* DOMINATES* 
Probability test is cost 
saving 0.53 0.39 0.62 0.68 0.80 0.84 0.90 
Probability test provides 
more benefit 0.73 0.73 0.74 0.73 0.73 0.73 0.73 
Probability that test is 
cost-effective  0.77 0.75 0.77 0.77 0.78 0.79 0.81 
Incremental Net Benefit 
(QALYs) (95% CI)** 
0.21 
(-0.87 – 1.21) 
0.17 
(-0.74 – 0.94) 
0.19 
(-0.71 – 0.93) 
0.21 
(-0.76 – 1.01) 
0.23 
(-0.77 – 1.04) 
0.23 
(-0.69 – 0.97) 
0.27 
(-0.69 – 1.08) 
        
Sensitivity analysis: Constant relative chemotherapy effect 
Probability that test is    
cost-effective  
0.33 0.31 0.41 0.35 0.36 0.50 0.43 
Incremental Net Benefit 
versus chemo for all 
(QALYs) (95% CI)* 
-0.09 -0.08 -0.05 -0.05 -0.03 -0.01 -0.02 
 
       
Sensitivity analysis: Variable survival after recurrence 
Probability that test is    
cost-effective versus 
chemo for all 
0.97 0.94 0.94 0.94 0.94 0.94 0.95 
Incremental Net Benefit 
versus chemo for all 
(QALYs) (95% CI)* 
0.70 0.54 0.54 0.60 0.61 0.58 0.66 
*’Dominates’ implies that the test is more effective and less costly than all patients receiving chemotherapy. 
**A positive incremental net benefit is necessary for a test to be considered more cost-effective than all patients receiving chemotherapy. 
The higher the incremental net benefit the more cost-effective the test is expected to be. 
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Value of Information Analysis 
The expected value of perfect information (EVPI), which represents the expected opportunity 
cost as a consequence of current decision uncertainty is 0.10 QALYs per patient on the Net 
Health Benefit scale or 3652 QALYs for the incident population in England over a 10 year time 
horizon.  
The EVPPI was high for all tests included in the base case analysis, suggesting high value in 
further research into test-directed chemotherapy regardless of which test is the focus of study 
(Figure 3). The EVPPI favoured Prosigna ROR as the preferred test for inclusion in further 
research. Ranking of the tests by EVPPI as seen in Figure 3 allows prioritisation between 
further tests. The Expected Value of Sample Information (EVSI) for an RCT comparing 
chemotherapy for all with chemotherapy directed by Prosigna ROR with a sample size of 2500 
patients per arm was £231 per patient or £8,397,961 for the 10 year incident population. This 
represents the expected UK health service value of such a trial. 
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Sensitivity analysis – chemotherapy effect 
In this analysis treating all patients with chemotherapy was more cost-effective than any of 
the testing options with a probability of individual tests being cost-effective ranging between 
31% and 50% (Table 3). The population EVPI was 4165 QALYs suggesting that further research 
may be worthwhile even if the chemotherapy effect is thought to be constant. The value of 
information analysis (Figure 3) shows the ranking of tests for research value which is of a 
notably different order compared with the base case results, suggesting high value into 
research on all test apart from MammaTyper.  
Sensitivity analysis – survival after recurrence 
Here it was assumed that post-recurrence survival is dependent on previous treatment with 
adjuvant chemotherapy and, by association, test score. Oncotype DX is favoured on the basis 
of expected cost-effectiveness, with Prosigna ROR falling into second place (Table 3). The 
population EVPI was 2353 QALYs. 
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DISCUSSION 
In the adjuvant treatment of early breast cancer, the notable survival gains seen at population 
level are at the cost of overtreatment and morbidity for many women, as well as unnecessary 
healthcare expenditure. Molecular testing offers a new era of enhanced risk stratification and 
may allow the prediction of which patients benefit, and therefore which patients may safely 
be spared chemotherapy. The potential efficiencies of such a strategy are very apparent, but 
the challenges of delivering an evidence base adequate to support adoption of this approach 
are significant and expensive given the large sample sizes required for RCTs of diagnostic 
tests. By considering the evidence requirements of not only clinical and scientific decision 
makers, but also health service and reimbursement decision makers earlier than is usual in 
the research and development process we have been able to optimise research design and 
research funding decisions within the OPTIMA programme.  
The overarching message is that molecular testing has huge potential both from a clinical and 
a cost-effectiveness perspective; but currently there is equally substantial uncertainty in the 
evidence base. There is undisputable value in generating robust evidence into molecular 
testing in our OPTIMA population and a decision to invest in the proposed trial can clearly be 
made. What is much less certain is which test is best or most cost effective. Based on the 
information provided by a future RCT primary endpoint of 5-year recurrence free survival, we 
have been able to rank different tests based on their research value. While it would be 
desirable to include all tests in a prospective future trial, the resources required for such 
would be unfeasible. By focussing future research on tests that offer best research value, we 
are maximising the chances of taking the correct test into practice in the long run.  
The key outcome measures of the OPTIMA prelim economic analysis, as qualified by the value 
of information analysis, remain unfamiliar to many; but we believe they are the correct metric 
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to answer research questions concerned with the efficient use of limited health care delivery 
and health research questions.  A pitfall that we sought to avoid was the use of statements of 
effectiveness or cost-effectiveness given the immaturity of much of the data contributing to 
this analysis. By focussing on decision uncertainty and the risk and consequences of 
suboptimal decision making we make balanced recommendations about research value, 
whilst avoiding statements that may prematurely be interpreted as practice-changing. The 
absence of data directly comparing the clinical validity of tests makes statements about cost-
effectiveness difficult to make and is an inevitable limitation of undertaking economic 
evaluation early in the technology development cycle. The quantification of uncertainties and 
research value is, however, more valid. This is because uncertainty in the comparative 
performance is quantitatively inflated in the model as a function of discordance with 
Oncotype DX.  As such the ranking of tests for research value is valid, whereas the ranking of 
tests for cost-effectiveness is more questionable. To clarify this point, note that ultimately a 
test which always selects patients in an identical manner to Oncotype DX will perform 
identically and therefore additional test-specific research will have no value. As with any 
model, it has limitations due to necessary assumptions; for example, late chemotherapy 
effects such as cardiac toxicity and second malignancies have not explicitly been modelled, 
survival distributions are assumed to be exponentially distributed and many of the model 
parameters including costs and quality of life have been derived from the literature, relying 
on studies that may not be exactly transferable to the setting under study. We hope that may 
of these limitations will be addressed within the ongoing OPTIMA research programme. 
A particularly important conclusion from this study is drawn from the sensitivity analysis 
which reveals that molecular tests need to predict chemotherapy effect and that 
prognostication of baseline risk is not enough for them to be cost-effective.  
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In conclusion, the economic analyses of the OPTIMA prelim trial have demonstrated that 
there is significant research value in pursuing a fully powered RCT with a 5-year recurrence 
free survival primary endpoint in the UK in a clinically high risk ER positive population. The 
choice of which test to include as the primary determinant of chemotherapy use is much less 
certain, but Prosigna ROR is currently ranked highest in terms of research value. Health 
economic modelling to inform a stop-go decision and the adaptation of an RCT looking at a 
diagnostic technology has been proven feasible as a method for improving research 
efficiency. 
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Section 1: Detailed description of model parameters 
Cancer recurrence rates and chemotherapy effect sizes 
Forecast recurrence free survival (RFS), assuming no chemotherapy, was derived for the 
OPTIMA prelim patient population using baseline clinical parameters entered into Adjuvant! 
Online (www.adjuvantonline.com). Full information on the parameters that underpin 
Adjuvant! Online has not been made public, therefore, in an attempt to represent likely 
parameter uncertainty, the sample standard deviation of the Adjuvant! Online RFS estimates 
was taken as a proxy for the standard error (se) of individual estimates.   
The only evidence for a predictive (variable chemotherapy benefit) effect in clinically high risk 
patients at the time of writing was based on retrospective Oncotype DX testing of patients in 
the SWOG88-14 trial (Table S1). This was represented in the economic model by a linear 
regression model, 
𝑙𝑜𝑔𝐻𝑅 =  𝛼 + 𝛽𝑅𝑆 
where logHR = the log hazard ratio for recurrence free survival, alpha = 0.4541 (se 0.03749), 
beta = -0.0238 (se 0.00418), RS = Recurrence Score and the correlation between alpha and 
beta is assumed to be -0.5. 
The resulting hazard ratio was applied to the no-chemotherapy recurrence rates for all 
individual patients in the “chemotherapy for all” standard care arm of the model over the first 
five years. In the “test-directed” arm of the model, the same chemotherapy effect was only 
applied to patients in the high-risk groups. Where there was no data providing evidence for 
the predictive ability of alternative tests, extra uncertainty was introduced into the model for 
these alternative tests depending on the degree of discordance between the test and 
Oncotype DX. For example, a completely concordant test will have identical predictive ability 
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and therefore no extra uncertainty is introduced. To achieve adequate representation of extra 
uncertainty, a suitable prior for the chemotherapy effect of the alternative test was required. 
In the absence of any informative information this prior treatment effect was represented by 
a hazard ratio of mean one with a very large standard deviation, assumed to be log-normally 
distributed. The choice of prior was subject to sensitivity analysis. 
In the base case model specification, post-recurrence survival was assumed to be 
independent of pre-treatment with adjuvant chemotherapy: the annual post-recurrence 
probability of death was assumed to be constant across groups with a mean of 0.30 (SD 0.22). 
Table s1 - Individual patient predicted hazard ratio for chemotherapy vs. no Chemotherapy for five-year disease free 
survival  
Oncotype DX recurrence score Hazard ratio  Upper 95% CI Lower 95% CI 
10 1.24 0.62 2.48 
18 1.03 0.58 1.81 
25 0.87 0.53 1.42 
31 0.75 0.48 1.18 
40 0.61 0.39 0.96 
CI, confidence interval. 
Chemotherapy treatment and toxicity 
The proportions of patients treated with anthracycline plus taxane, anthracycline alone, or 
taxane alone were estimated from OPTIMA prelim data. Chemotherapy toxicity rates were 
estimated from landmark chemotherapy clinical trials (Table S2).2–4 Toxicity rates for FEC100-
Pw were assumed to be equivalent to FEC100-T, and toxicity rates for epirubicin (E) were 
assumed to be equivalent to FEC.  Toxicity rates for FEC75 were assumed to be equivalent to 
two-thirds the rates for FEC100. 
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TABLE S2 - Chemotherapy toxicity rates from landmark trials 
Parameter Mean 
 
Distribution Source 
 
TC (USO 9735 trial) N = 506 
 
 Jones et al, 2009 
Febrile Neutropenia 0.046  Beta(23,483)  
Anaemia 0.010  Beta(5,501)  
Thrombocytopenia 0.005  Beta(2,504)  
Stomatitis 0.008  Beta(4,502)  
Diarrhoea 0.025  Beta(12,494)  
Nausea and vomiting 0.030  Beta(15,491)  
 
FEC100 (PACS-01) 
 
N=995 
  
Roche et al, 2006 
Febrile Neutropenia 0.084  Beta(84,911)  
Anaemia 0.014  Beta(14,981)  
Thrombocytopenia 0.003  Beta(3,992)  
Stomatitis 0.04  Beta(40,955)  
Diarrhoea 0  Beta(1,996)  
Nausea and vomiting 0.205  Beta(204,791)  
 
FEC100-T (PACS-01) 
 
N=1001 
  
Roche et al, 2006 
Febrile Neutropenia 0.112  Beta(112,889)  
Anaemia 0.007  Beta(7,994)  
Thrombocytopenia 0.004  Beta(4,997)  
Stomatitis 0.059  Beta(59,942)  
Diarrhoea 0  Beta(1,1002)  
Nausea and vomiting 0.112  Beta(112,889)  
E-CMF (TACT2) N=1029   
 
Cameron et al, 2010 
Febrile Neutropenia     0.13  Beta(137,892)  
Anaemia     0.03  Beta(31,998)  
Thrombocytopenia     0.01  Beta(10,1019)  
Stomatitis     0.00  Beta(1,1030)  
Nausea and vomiting     0.04  Beta(46,983)  
Diarrhoea     0.02  Beta(24,1005)  
 
Late effects 
Parameters are included in Table S3 (Table . Population age and gender-specific incidence of 
congestive heart failure were taken from Office of National Statistics published data as 
presented by the British Heart Foundation.5 The lifetime relative risk of congestive cardiac 
failure after chemotherapy was based on data from the Oxford Overviews and applied to the 
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population incidence, to provide an estimate of excess congestive heart failure due to 
chemotherapy.6 Mortality after onset of congestive cardiac failure was taken from a UK 
population study.7 
The age and gender-specific incidence rate of acute myeloid leukaemia was taken from a large 
UK primary care derived population database.8 There is evidence for an increased relative risk 
of acute myeloid leukaemia in patients treated with chemotherapy from a number of 
published pooled trial-based analyses, but this was difficult to estimate reliably due to the 
low absolute numbers of observed events.6,9–12 A relative risk of two was therefore specified 
in the model, but was assigned a very high standard error to reflect this uncertainty.   Survival 
after a diagnosis of acute myeloid leukaemia was based on UK Cancer Registry statistics, as 
provided in a report by the Northern and Yorkshire Cancer Registration and Information 
Service (NYCRIS).13 
Other transition probabilities and proportions 
The mean time from metastatic recurrence to death was estimated from a UK patient level 
analysis of 1000 consecutive breast cancer patients in a single NHS Trust with a minimum of 
ten years follow-up.14 An estimate of the proportion of recurrences that are locoregional was 
taken from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial, which included a 
large number of UK patients with similar characteristics to patients enrolled into OPTIMA 
prelim.15 Background age-specific non-breast cancer mortality was estimated by subtracting 
age-specific breast cancer–specific mortality from the age and gender-specific background 
mortality, obtained from the UK Office of National Statistics.16 
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Table S3 - Transition probabilities and proportions 
Parameter Mean se Distribution Notes Source 
Proportion 
locoregional vs 
distant 
recurrence 
0·31 0.015 Beta Proportion of 
recurrences that are 
local to the original 
breast cancer primary 
Baum et al, 2003  
Death after 
distant 
recurrence 
0·30 0.025 Beta Annual probability of 
death after a distant 
recurrence (ER +ve) 
Walkington et al, 
2012  
Background 
mortality 
Age -
specific 
 fixed Life tables Office of National 
Statistics, 2009  
Chemo-
associated excess 
mortality (first 
year) 
0.0024 0.0019 Beta 2.4% age 55-69 EBCTCG, 2012 
      
Background rate 
CHF 
Age-
specific 
 fixed Annual age-specific 
female incidence of CHF  
Townsend et al, 2012  
Relative risk of 
CHF with 
anthracycline 
treatment 
1·61 0.31 Log-normal Applied as a constant 
lifetime risk 
EBCTCG, 2012 
Death after CHF 0.6 0.033 Beta Hillingdon study  Cowie et al, 2000  
      
Background 
annual rate AML 
(female, age 60-
79) 
0.00296 fixed fixed  Bhayat et al, 2009  
Relative risk of 
AML after chemo 
7.6 7.1 Log-normal NCCN analysis 12 
Relative 5-year 
survival for AML 
(female,age 65+) 
0.0383 0.0048 Beta Assumes constant 
relative survival, applied 
to background mortality 
rate 
Oliver et al, 2013  
se, standard error; ER, estrogen receptor. 
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Costs 
Costs were adjusted to a base year of 2013-2014 using the Hospital and Community Health 
Service (HCHS) pay and prices index published by the Personal Social Services Research Unit 
(PSSRU). In the probabilistic analysis costs were assumed to have a log-normal distribution. 
The additional expected healthcare costs in patients receiving chemotherapy were derived by 
combining the expected costs of chemotherapy procurement and delivery with those 
expected from follow-up. Assumptions were made about routine practice in the UK NHS 
based on advice from oncologists in London, Edinburgh and Leeds: 
 Chemotherapy regimens represented in the economic model are FEC100, FEC100-T, 
FEC-Pw, TC,  and E-CMF. 
 Average body surface area 1.7 m2 
 Relative Dose Intensity 92% (all planned cycles completed). 
 No vial sharing permitted (remaining drugs in vials assumed to be wasted)  
 Standard supportive medication, procurement, laboratory, pharmacy and 
administration costs are based on eMIT, BNF and NHS reference costs. 
 Two medical oncology clinic visits per regimen and one specialist nurse review per 
cycle. 
 Granulocyte colony-stimulating factor (GCSF) (5x doses of filgrastim 300mcg) for 50% 
of FEC, 100% of FEC-T and 0% of TC and E-CMF cycles.    
 Aprepitant is used as a prophylactic anti-emetic for 20% of FEC cycles. 
 Grade 3 and 4 acute toxicity rates as per the PACS-01, USO 9735 and TACT2 
trials (including febrile neutropenia rates for TC=4.6%, FEC100=8.4%, FEC100-
T=11.2% and E-CMF=13%).  
 50% of toxicity-related hospital admissions were assumed to be greater than two 
days (long stay) and 50% were assumed to be less than two days (short stay) 
 15% of patients have a central line inserted (but associated complications of this are 
not costed). 
 Community healthcare costs, out-of-pocket patient and carer costs, and costs due to 
future lost-productivity are not included.   
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 Value Added Tax (VAT) is not included on drug costs. 
Unit costs for on-chemotherapy grade 3 and 4 toxicity were taken from the UK NHS reference 
costs. 17 A full breakdown of chemotherapy costs is given in Tables S4 to S7. 
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Table S4 - Chemotherapy drug costs per cycle 
Regimen Drug Dose 
mg/m2 
Dose 
(mg/patient) 
Vial size 
(ml) 
Vial 
strength 
(mg/ml) 
Mg per 
vial 
Price per 
vial 
No 
vials/ 
cycle 
Drug 
cost/ 
cycle 
FEC100 
 
 
Fluorouracil a 500 782 10 25 250  £     3.20  4  £    12.80  
Epirubicin b 100 156.4 100 2 200  £   27.87  1  £    27.87  
Cyclophosphamide  a 500 782   1000  £   17.06  1  £    17.06  
TC 
 
Docetaxel b 75 117.3 7 20 140  £    35.74  1  £    35.74  
Cyclophosphamide  a 600 938.4   1000  £    17.06  1  £    17.06  
FEC100-T Fluorouracil  a 500 782 10 25 250  £      3.20  4  £    12.80  
Epirubicin b 100 156.4 100 2 200  £    27.87  1  £    27.87 
Cyclophosphamide a 500 782   1000  £    17.06  1  £    17.06  
FEC100-T Docetaxel b 100 156.4 8 20 160  £    44.55  1  £    44.55  
E-CMF Epirubicinb 
Cyclophosphamidea 
Methotrexatea 
Flourouracila 
100 
600 
40 
600 
156.4 
938.4 
62.56 
938.4 
100 
 
2 
10 
2 
 
25 
25 
200 
1000 
50 
250 
£     27.87 
£     17.06 
£       2.62 
£       3.20 
1 
2 
4 
8 
£     27.87 
£     34.12 
£     10.48 
£     25.60 
FEC75 Flourouracila 
Epirubicinb 
Cyclophosphamidea 
500 
75 
500 
782 
117.3 
782 
10 
100 
 
25 
2 
 
250 
200 
1000 
£       3.20 
£     27.87 
£     17.06 
4 
1 
1 
£     12.80 
£     27.87 
£     17.06 
FEC100-Pw Fluorouracil a 
Epirubicinb 
Cyclophosphamidea 
Paclitaxelb 
500 
100 
500 
80 
782 
156.4 
782 
136 
10 
100 
 
25 
25 
2 
 
 
250 
200 
1000 
150 
£       3.20 
£     27.88 
£     17.06 
£     11.26 
4 
1 
1 
3 
 £    12.80  
£     27.88 
£     17.06 
£     33.78 
Assumes average surface area of 1.7m2 and a relative dose intensity of 92%. 1 cycle of Pw = 3 doses given weekly. 
a British National Formulary 2013 
b Department of Health Commercial Medicines Unit (CMU) electronic Market Information Tool (eMIT) 
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Table S5 - Supportive medications 
 
Unit 
dose 
Unit 
cost 
Units 
per 
cycle 
% 
use Per cycle 
 
Total cost of supportive 
medications per cycle 
Dexamethasone (oral) a 2mg  £0.03  20 1  £0.60   FEC100+50%GCSF £ 145.21 
Dexamethasone (IV) a 3.3mg  £0.40  8 1  £3.20   FEC100+GCSF £ 276.96 
Ondansetron a 
 
8mg 
 
 £0.15  
 
1 
 
1 
 
 £0.15  
 
 T+GCSF 
FEC75 
CMF 
£ 267.48 
£  13.46  
£    0.36 
Aprepitant (pre-made 
pack) b  
1 pack  £47.42  1 0.2  £9.48   
TC £     3.98 
Metoclopramide a 10mg  £0.01  7 0.5  £0.03   P £     0.08 
Filgrastim (GCSF) b, c * 300mcg  £52.70  5 1*  £263.50   E £     0.03 
b British National Formulary 2013 
a Commercial Medicines Unit (CMU) electronic Market Information Tool (eMIT) 
c GCSF is used for 100% of FEC-T cycles, 50% of FEC100 cycles and 0% of TC cycles 
 
Table S6 - On-chemotherapy toxicity costs derived from the NHS reference costs 
Parameter Mean (£)   HRG code 
Toxicity (grade 3 & 4) HRG – short stay 
  Anaemia 644   PA48B 
  Febrile neutropenia 877   PA45Z 
  Nausea 340   PA28B 
  Diarrhoea 356   PA26B 
  Thrombocytopenia 540   SA12K 
  Stomatitis 387   CZ23Y 
Toxicity (grade 3 & 4) HRG – long stay 
  Anaemia 1,099   PA48B 
  Febrile neutropenia 3,485   PA45Z 
  Nausea 856   PA28B 
  Diarrhoea 1,107   PA26B 
  Thrombocytopenia 1,311   SA12K 
  Stomatitis 1,551   CZ23Y 
HRG, Healthcare Resource Group 
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Table S7 - Overall costs per regimen (assuming 50% short stay AND 50% LONG STAY for toxicity) 
Drug 
Regimen   
(no. cycles) 
Central 
line 
costs 
Drug 
costs 
Delivery 
costs 
Supportive 
meds  
Medical 
oncology 
costs 
Specialist 
nurse 
review 
Blood 
tests 
Toxicity 
costs 
Total cost  
FEC100 (6) £18.17 £346.38 £1,284.58 £871.27 £310.81 £613.10 £62.32 £359.53 £3,866.17 
FEC100-T  
(3 + 3) 
£18.17 £306.84 £1,284.58 £1,238.07 £450.03 £613.10 £62.32 £378.18 £4,351.30 
TC (4) £18.17 £211.20 £856.39 £15.91 £310.81 £408.74 £41.55 £158.16 £2,020.93 
FEC75 (6) £18.17 £346.38 £1,284.58 £80.77 £310.81 £613.10 £62.32 £239.69 £2,955.82 
Epi-CMF  
(4 + 4) 
£18.17 £392.28 £2,569.16 £1.54 £450.03 £817.47 £124.64 £360.10 £4,733.39 
FEC100-Pw 
(3 + 3) 
£18.17 £274.53 £2,569.16 £435.89 £450.03 £613.10 £124.64 £378.18 £4,863.70 
 
The mean annual costs of disease-free and cancer recurrence health states were estimated 
from an updated audit of hospital income recorded (Table S8).18 These costs are based on the 
national Payment by Results tariff produced by the UK Department of Health specific to each 
year in which they were incurred, adjusted for inflation to the base year for the analysis. 
Patient data was censored at last follow-up contact and the Kaplan-Meier Sample Average 
cost method was used to adjust for censoring.19 The annual cost of the disease-free state was 
based on year two onwards costs under the assumption that this represents the costs of 
follow-up minus chemotherapy costs.  
Table S8 - Disease-free and cancer recurrence health state annual costs 
Parameter Mean (£) SE 
COSTS   
Disease free (annual cost excluding chemo-related costs) 1,000.31 3.83 
Disease free after local recurrence (annual, year 2 on) 1,354.17 151 
Local recurrence (first year) 6,126.35 517 
Distant recurrence (annual) 1,681.53 32 
SE, standard error 
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Test costs 
Test costs were calculated on a per sample basis using current list prices and data from 
manufacturers. Where a list price was not available in the public domain, the manufacturers 
were asked for an expected UK price. Any anticipated NHS discounts were not considered. 
Any assumptions used in the cost calculations were based on expert opinion. Costs were 
converted to 2013 pound sterling (GBP £) using the following exchange rates: GBP to EURO 
(€) = 0.825, and USD ($) to GBP = 0.60.  
All tests were assumed to be exempt from VAT: for tests conducted within the NHS it was 
assumed that all NHS purchasing was operated under a Managed Service Contract (which 
excludes VAT); similarly tests conducted by commercial institutions for the NHS are exempt 
from VAT. For tests conducted within NHS laboratories, labour costs were calculated based 
on estimates of the overall time to run assay samples, and did not include sectioning time, 
pathologist time to mark areas for extraction and for reporting.  
Oncotype DX: For Oncotype DX, tests are sent to the manufacturer (Genomic Health) to 
complete and return, with no additional costs to the NHS. The cost for Oncotype DX is based 
on the manufacturer list price at the time of analysis (£2580). 
MammaPrint/BluePrint: Tests are sent to the manufacturer to complete and return, with no 
additional costs to the NHS.  The advertised list price, confirmed by manufacturer at the time 
of analysis, was 2675 Euro excluding VAT, equivalent to GBP £2,207.  
Prosigna: Testing requires the purchase or lease of a nanoString instrument in addition to 
individual assay kits in order to process samples within the NHS. The cost per test therefore 
depends upon the machine capital costs (purchase and services), the assay cost, ribonucleic 
acid (RNA) extraction/ preparation, and the labour costs. These are summarized below.    
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1) Capital costs: 
Machine purchase, lifetime and service costs were communicated by the manufacturer at the 
time of the analysis:  
o Machine purchase – US$ 285,000 = GBP £171,000.  
o Machine expected lifetime – 5 years 
o Service cost – US$ 15,000/year = $75,000/ 5 years = GBP £45,000/ 5 years 
o Total capital cost per site = £216,000 per 5 years 
 
The expected number of tests required is 4376 per year (Cancer Registry data). Assuming five 
sites within the NHS, then 875 tests are required per year, per site. Capital cost per test (five 
sites) is therefore £216,000/5/875 = £49.37. There is uncertainty around the number of 
instruments that would be purchased across England. Assuming three sites we have a lower 
(25th) quartile value of £29.61 and assuming ten sites we have an upper (75th) quartile value 
of £98.72.  
2) Assay cost: 
Prosigna Assay - £1,277 (manufacturer quoted UK cost) 
Cartridge sizes – four or ten  
Each cartridge pack includes one quality assurance (QA) sample, and an entire cartridge must 
be used at once; any unused cartridges from the pack are wasted. Thus a pack of four can run 
a maximum of three samples plus one QA test and a pack of ten can run up to nine samples.  
Assuming a five day working week, 52 weeks/year, and excluding Christmas and New Year 
(three days), there are ~257 ((52x5)-3) working days in a year. Assuming five sites, to complete 
875 tests per year requires completing (on average) 3.4 tests per day per site, or 17 per week 
per site. Assays are assumed to be batched on a weekly basis. Therefore running 17 tests per 
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week requires two cartridges of size ten, with wastage of one sample. We therefore assume 
that on average cartridge sizes of size ten are used with one sample wasted.  
The expected assay cost is therefore £1,596.25/ test (£1277 x 10/8). 
There is uncertainty around the number of samples that would be wasted per cartridge. This 
is represented in the model using a lognormal distribution with a lower bound of £1,418.89/ 
test (assuming maximum number of 9 samples run using cartridge size ten i.e. £1277x10/9) 
and an upper bound of £5108/ test (assuming minimum number of 1 samples run using 
cartridge size four i.e. £1277x4/1), assuming these bounds are 95% confidence intervals.  
3) Labour cost: 
Biomedical scientist time: assuming “batching” of tests in groups of 17 (plus two controls) it 
is estimated that 11 hours of hands-on time are required for the macro-dissection, RNA 
extraction and assay set up. This equates to 39 minutes of biomedical scientist time per test. 
Valued at an agenda-for-change grade seven technician hourly rate of £22.98, this equates to 
£14.94 labour cost.  
4) RNA extraction/preparation materials: 
USD $500 for 25 isolations using Roche kit (US$ 20/ sample = GBP £12 per sample; 
communication with manufacturer).  
Total cost per Prosigna test:  Capital cost per test (£49.37) + assay cost (£1,596.25) + RNA 
extraction cost (£12) + labour cost (£14.94) = £1672.56.  
Incorporating uncertainties around the capital cost, assay cost and labour costs gives a 
lognormal distribution, with mean £1672.50 and standard deviation £50.94 (mu = 7.422, 
sigma = 0.030). 
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MammaTyper: Testing requires the purchase or lease of a Roche LightCycler real-time PCR 
platform. The cost per test therefore depends upon the machine capital costs (purchase and 
servicing), the assay cost, RNA extraction, preparation and the labour costs. These are 
summarized below.    
1) Capital costs: 
Capital costs include a Roche Diagnostics LightCycler real-time PCR machine. Purchase and 
service costs of the LightCycler machine were communicated by Roche at the time of the 
analysis:  
o LightCycler LC/Z480 (96 well) machine purchase – GBP £23,500.  
o Machine expected lifetime – 10 years 
o Service cost – 10% of purchase cost from year 2 = £21,150 (to 10 years) 
o Total capital cost per site = £44,650 over 10 years 
 
The expected number of tests required is 4376 per year (bespoke analysis by Public Health 
England Cancer Registry). Assuming five sites within the NHS, then 875 tests are required per 
year, per site. Capital cost per test (five sites) is therefore (£44650*5)/(4376*10) = £5.102. 
There is uncertainty around the number of instruments that would be purchased across 
England. Assuming three sites we have a lower (25th) quartile value of £3.061 and assuming 
ten sites we have an upper (75th) quartile value of £10.203. 
2) Assay cost: 
MamaTyper Assay - £1277 (Interquartile range 400 – 1400) (analyst estimated UK price) 
MammaTyper tests are purchased in batches of 10 (8 tests + 2 controls).  
Two controls need to be included with each rtPCR run. Controls can be reused/thawed up to 
three times. 
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Assuming a five day working week, 52 weeks/year, and excluding Christmas and New Year 
(three days), there are ~257 ((52x5)-3) working days in a year. Assuming five sites, to complete 
875 tests per year requires completing (on average) 3.4 tests per day per site, or 17 per week 
per site. Assays are assumed to be batched on a weekly basis. Therefore running 17 tests per 
week in a single batch with two controls. 
The expected assay cost is therefore £1596 per test (price*10/8) (IQR 500-1750). 
3) Labour cost: 
Biomedical scientist time: assuming “batching” of tests in groups of 17 (plus two controls) it 
is estimated that 11 hours of hands-on time are required for the macro-dissection, RNA 
extraction and assay set up. MammaTyper preparation, set up master mixes, distribute 
master mixes and set up real time instrument is estimated at 1 hour. This equates to 42 
minutes of biomedical scientist time per test. Valued at an agenda-for-change grade seven 
technician hourly rate of £22.98, this equates to £16.09 labour cost.  
4) RNA extraction/preparation materials: 
£283 for 50 isolations using Roche kit £12 per sample.  
Total cost per MammaTyper test:  Capital cost per test (£5.102) + assay cost (£1596) + RNA 
extraction cost (£12) + labour cost (£16.09) = £1629.192 (Interquartile range 531.15 – 
1788.29).  
Incorporating uncertainties around the capital cost, assay cost and labour costs gives a 
lognormal distribution, with mean £1629.19 and standard deviation £1905.11 (mu = 6.991, 
sigma = 0.899). 
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IHC4 AQUA: Price provided by the manufacturer in 2014 for in-house/central commercial 
testing was $1200 (GBP £720).  
IHC4: For IHC4 performed using routine staining methods, costs of staining are relatively 
simple to estimate however, due to the quantitative nature of the IHC4 score additional 
pathological assessment is required to accurately estimate ER histoscores and PgR and Ki67 
percentage positive cells within the narrow bands (30 units or 10%) required.  
Within the OPTIMA prelim study IHC4 was performed in a central laboratory, using tissue 
microarrays and image analysis, which does not reflect routine diagnostic practice (where 
whole slides are assessed) and precludes accurate assessment of test costs as they would be 
in an NHS setting. No formal measurement of the time required by individual pathologists to 
perform the additional quantification required for this test is available to provide a cost 
estimate was undertaken within OPTIMA prelim. For the purposes of the economic model, 
the time taken for IHC4 was estimated by consultation with NHS pathologists and laboratory 
managers.  
All IHC4 testing was assumed to be conducted at local hospitals and laboratories, using 
currently available technology. Block selection and retrieval was not costed as these are 
already routinely conducted within the NHS. The cost of consultant time was assumed to be 
£157 per hour based on PSSRU unit costs. The calculation of the IHC4 cost per test was as 
follows: 
ER - £26 (10 mins) extra pathologist time  
PR - £15 consumables/lab costs + £26 (10 mins) pathologist time 
Ki67 - £20 consumables/lab costs + £52 (20 mins) extra pathologist time  
HER2 – no extra cost 
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Generation of IHC4 report via algorithm - £13 (5 mins of pathologist time) 
Total cost per test = £152  
As there remains uncertainty about this estimate, which is based on expert opinion, therefore 
it will be represented as an uncertain parameter in the OPTIMA model, with mean £152 and 
interquartile range £116 - £207 (sd 69) (implying that there is a 50% chance that the true cost 
lies within this range). Represented in the model by a lognormal distribution with parameters 
mu=4.93 and sigma=0.429 
Utilities  
A literature review was carried out to update the relevant health utility values for the OPTIMA 
model from a previously published relevant systematic review (Table S9).20  Full details of the 
search strategy, literature review method and data extraction are available on request. 
 
Table S9 – Utility parameters 
Utilities   
 Mean sd Distribution  Source 
Starting utility Age group specific 
60-64 = 0.81 
65-74 = 0.78 
75-100 = 0.71 
fixed na  Kind et al 1998 21  
Disease free (no chemo) a -0.003 0.03 lognormal  Campbell, 201122  
Disease free (on chemo) a -0.099 0.033 lognormal  Campbell, 201122 
Local recurrence a -0.108 0.04 lognormal  Campbell, 2011 22 
Distant recurrence a -0.303 0.16 lognormal  Campbell, 2011 22 
Congestive heart failure 0·528 0.047 beta  Kirsch, 2000 23 
a decrement from age and sex matched controls 
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Section 2: Parameterisation of Sensitivity Analyses 
Sensitivity Analysis 1: Constant benefit from chemotherapy 
Chemotherapy benefit from the Oxford Overview meta-analysis was applied to the predicted 
recurrence-free survival (RFS) over a 5-year period for patients receiving chemotherapy in the 
model. The hazard ratio for RFS for anthracycline chemotherapy was taken to be 0.69 (SE 
0.04) over the first 5 years with an additional benefit from the addition of a taxane of 0.84 
(95%CI 0.78-0.91).6 A limitation of this approach is that it only allows incorporation of 
uncertainty around the forecast where full information is available about the prognostic 
model; such information is not available for Adjuvant!. Therefore, in an attempt to represent 
likely uncertainty, the sample standard deviation of the Adjuvant! RFS estimates was taken as 
a proxy for the standard error of individual estimates. 
 
Sensitivity Analysis 2: Survival after cancer recurrence varies depending on whether patients 
received chemotherapy as adjuvant therapy for their early cancer. 
It is likely that patients who have received adjuvant chemotherapy will survive for a different 
length of time after a recurrence compared to those who did not receive adjuvant 
chemotherapy. In the base-case  the  annual  post-recurrence  probability  of  death  was  
assumed  to  be  0.30  (SD  0.22).  In sensitivity analysis 2 the annual probability of death after 
recurrence varied depending on whether previous adjuvant chemotherapy had been given. 
Given that overall survival is available for  the  SWOG88-14  trial,  the  post-recurrence  survival  
parameter  was  derived  by  calibrating  the economic model against this outcome measure. 
The resulting annual probability of death following recurrence  is  therefore  0.40  (standard  
deviation  (SD)  0.17)  for  patients  treated  with  adjuvant chemotherapy and 0.14 (SD 0.17) 
for patients who did not receive adjuvant chemotherapy and who had a low Oncotype DX RS. 
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Section 3: Incident population calculations for value of information 
analysis 
There is very little evidence to inform this parameter in the relevant patient populations. 
Given that overall survival is available for the SWOG88-14 trial, the post-recurrence survival 
parameter was derived by calibrating the model against this outcome measure. The resulting 
annual probability of death following recurrence is therefore 0.40 (standard deviation (SD) 
0.17) for patients treated with adjuvant chemotherapy and 0.14 (SD 0.17) for patients who 
did not receive adjuvant chemotherapy and who had a low Oncotype DX RS.  
In order to provide an estimate of total value of information an estimate of number of 
patients for whom the reimbursement decision is pertinent is required. Based on information 
provided by the West-midlands cancer registration service, the annual incident population of 
patients eligible for OPTIMA in England alone is around 4376 patients (Table S10). It should 
be noted that the quality of cancer registration data is higher in the West-midlands region 
than other regions.  The West-Midlands population diagnosed of breast cancer represents 
10.9% of the total English population of patients diagnosed with breast cancer. English 
estimates are therefore based on a multiple of the West-Midlands estimate rather than data 
for the whole of England. The pertinent time horizon for the decision problem was assumed 
to be ten years. 
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Table S10: Annual incident patient population eligible for the OPTIMA trial. 
Cohort: women diagnosed with invasive 
breast cancer in 2010 (calendar year) 
Women diagnosed in 
WEST MIDLANDS 
region 
Number % 
Number of women diagnosed with at least 
one invasive (*) breast cancer tumour in 
2010 
                     
4,456  
100% 
Criteria     
 [Women aged 40 or more] 
                     
4,280  
96.1% 
& [tumour was surgically treated] 
                     
3,550  
79.7% 
& [tumour was ER positive] 
                     
2,969  
66.6% 
& [tumour was HER2 negative] 
                     
2,440  
54.8% 
&( [1 to 9 positive axillary lymph nodes] 
OR [axillary lymph nodes were negative 
AND invasive tumour size > 30mm]) 
                        
877  
19.7% 
& [patient was treated with 
chemotherapy]  
                        
485  
10.9% 
& [patient was MO or Mx at diagnosis] (i.e 
no known metastases at diagnosis) 
                        
477  
10.7% 
*invasive = excluding micro-invasive tumours 
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